CD-Venture
15
14M
9
0.75
0.40
4
- Stages of investment
- Areas of investment
Summary
The fund was located in Europe if to be more exact in Germany. The leading representative office of defined VC is situated in the Heidelberg.
The typical case for the fund is to invest in rounds with 7-8 participants. Despite the CD-Venture, startups are often financed by Forbion Capital Partners, NGN Capital, Arcus Ventures. The meaningful sponsors for the fund in investment in the same round are Forbion Capital Partners, Yabeo Capital, Partnership Fund for New York City. In the next rounds fund is usually obtained by Shortcut Ventures GmbH, NGN Capital, Forbion Capital Partners.
The overall number of key employees were 1.
Moreover, a startup needs to be at the age of 6-10 years to get the investment from the fund. We can highlight the next thriving fund investment areas, such as Biotechnology, Medical Device. Among the most popular portfolio startups of the fund, we may highlight GenomeDx Biosciences, Exosome Diagnostics, Wellth. For fund there is a match between the location of its establishment and the land of its numerous investments - Germany. The fund has no exact preference in some founders of portfolio startups. In case when startup counts 4 or 5+ of the founder, the chance for it to get the investment is meager.
The important activity for fund was in 2015. Comparing to the other companies, this CD-Venture performs on 15 percentage points more the average number of lead investments. The higher amount of exits for fund were in 2015. Deals in the range of 10 - 50 millions dollars are the general things for fund. The fund is generally included in less than 2 deals every year.
Investments analytics
Analytics
- Total investments
- 15
- Lead investments
- 0
- Exits
- 4
- Rounds per year
- 0.75
- Follow on index
- 0.40
- Investments by industry
- Health Care (12)
- Biotechnology (10)
- Genetics (6)
- Health Diagnostics (5)
- Medical (5) Show 11 more
- Investments by region
-
- United States (8)
- Germany (6)
- Canada (1)
- Peak activity year
- 2014
Discover reliable insights
Leverage validated data, identify key contacts and secure funding opportunities for your business.Quantitative data
- Avg. startup age at the time of investment
- 13
- Avg. valuation at time of investment
- 52M
- Group Appearance index
- 1.00
- Avg. company exit year
- 12
- Avg. multiplicator
- 3.32
Need more data?
Get access to full data about investors, including their team, contact information, and historic data.
Latest deals
| Company name | Deal date | Industry | Deal stage | Deal size | Location |
|---|---|---|---|---|---|
| Panaya | 18 Apr 2006 | Software, SaaS, Enterprise Software, Enterprise Applications, Risk Management, Enterprise Resource Planning (ERP), Quality Assurance | Early Stage Venture | 5M | United States, New Jersey |
| Phenex Pharmaceuticals | 21 Sep 2010 | Biotechnology, Pharmaceutical, Biopharma | Late Stage Venture | 7M | Germany, Baden-Württemberg, Heidelberg |
| Wellth | 30 Mar 2023 | Information Technology, Health Care, Personal Health, mHealth | Early Stage Venture | 20M | United States, California, Los Angeles |
Similar funds
By same location
By same geo focus
By doing lead investments
At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).
Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.